期刊文献+

精神疾病患者合并躯体疾病的诊治策略 被引量:8

Diagnosis and treatment of psychotic patients complicated with physical diseases
原文传递
导出
摘要 目的探讨精神疾病患者合并躯体疾病的特点及诊治方法。方法对351例精神疾病合并躯体疾病患者的临床资料进行回顾性分析。结果 351例患者都能及时得到确诊和治疗;有249例痊愈,3例死亡,99例在出院后还需服用躯体疾病治疗药物。对这99例患者随访1年,12例失访,78例病情稳定,9例因服药不规范而复发。结论精神疾病患者合并躯体疾病的诊治需要运用一些技巧,治疗上更要注意避免药物间的相互作用和精神科药物对躯体疾病的影响。 Objective To explore the clinical characteristics, diagnosis and treatment of psychotic patients cornplicated with physical diseases, and to sum up clinical experience. Methods Clinical data of 351 psychotic patients complicated with physical diseases were reviewed. Results All of 351 patients were diagnosed on time. There were 249 patients cured, 99 patients must Continue to take physical drugs after discharge. There were 3 patients died.Of patients to continue to follow-up for 1 year.78 patients in stable condition, 9 cases of recurrence for medication is irregular. Conclusion It' s difficulty to diagnosis and treat a psychotic patient complicated with physical diseases. It' s necessary to use some skills at the same time also pay attention to drug interactions and antipsychotic drugs to the influence of physical disease.
出处 《国际精神病学杂志》 2016年第2期288-290,共3页 Journal Of International Psychiatry
关键词 精神疾病患者 合并 躯体疾病 诊治 Psychiatric patients Complicated with Physical diseases Diagnosis and treatment
  • 相关文献

参考文献5

二级参考文献40

  • 1Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal, joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2005, 28 (9) : 2289 - 2304.
  • 2Basson B, Kinon B, Taylor C, et al. Factors influencing weight change in patients with schizophrenia treated with olanzapine versus haloperidol or risperidone. J Clin Psychiat, 2001, 62(4): 231 - 238.
  • 3Poyurovsky M, lsaacs I, Fuchs C, et al. Attenuation of olanzapine - induced weight gain with reboxetine in patients with schizophrenia: a double - blind, placebo - controlled study. Am J Psychiat, 2003, 160 (2) : 297 - 302.
  • 4Allison D, Mentore J, Heo M, et al. Antipsychotic - induced weight gain: a comprehensive research synthesis. Am J Psychiat, 1999, 156 ( 11 ) : 1686 - 1696.
  • 5Lieberman J, Stroup T, McEvoy J, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med, 2005, 353(12) : 1209 -1223.
  • 6McEvoy J, Lieberman J, Perkins D, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double - blind 52 - week comparison. Am J Psychiat, 2007, 164(7) : 1050 - 1060.
  • 7Breier A, Berg P, Thakore J, et al. Olanzapine versus ziprasidone: results of a 28 - week douhle - hlind study in patients with schizophrenia. Am J Psychiat, 2005, 162(10) : 1879 -1887.
  • 8Kinon B, Lipkovich I, Edwards S, et al. A 24 - week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol, 2006, 26(2) : 157 -162.
  • 9Simpson G, Glick I, Weiden P, et al. Randomized, controlled, double - blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiat, 2004, 161 (10) : 1837 - 1847.
  • 10Su K, Wu P, Pariante C. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacol, 2005, 183(3) : 383 -386.

共引文献69

同被引文献45

引证文献8

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部